Treatment with psychedelics is psychotherapy: beyond reductionism

Since the 1950s the relative contributions of psychotropic drugs and psychotherapy to psychiatric outcomes have been fiercely debated. In the context of psychedelic treatments, this debate has re-emerged because these interventions traditionally combine potent pharmacology with structured psychotherapeutic support. Some recent proposals and regulatory views treat psychedelic effects as separable from their psychosocial context, attributing therapeutic benefit primarily to the substance and framing therapist contact as safety-focused rather than therapeutically active. Gründer and colleagues set out to contest that reductionist framing. In this Personal View they argue that the effects of psychedelics are inherently context dependent, that psychotherapy is central to safety and efficacy, and that regulatory and research approaches should recognise treatment with psychedelics as a form of psychotherapy rather than as a purely biological intervention. The piece aims to bring clinical, translational, historical, and regulatory perspectives to bear on this argument and to urge changes in how such treatments are studied, regulated, and implemented.

This paper is a Personal View rather than an empirical study. Rather than reporting a systematic review or original quantitative analyses, Gründer and colleagues marshal theoretical models, historical descriptions of psychedelic therapy, selected animal and human findings, examples from large clinical trials and guidelines, and regulatory and health-technology-assessment (HTA) perspectives to build a conceptual argument. The extracted text does not describe a formal search strategy, inclusion criteria, or risk-of-bias assessment. Instead, the investigators cite illustrative evidence (for example, preclinical work on plasticity, clinical trial protocols and guideline recommendations, and HTA decisions) and describe historical treatment modalities (psycholytic versus high-dose psychedelic approaches) and current clinical-trial practices (preparation, dosing-session support, and integration). The contributors statement notes that Gründer wrote the first draft and all authors reviewed and revised the manuscript. No new primary data collection or statistical analyses are reported in the extracted text.

Gründer and colleagues present several interlocking lines of evidence and argument to support their claim that psychedelic treatment is psychotherapy in practice and principle. First, they emphasise context dependence of psychotropic effects. They invoke the "undirected susceptibility to change" model, whereby drugs such as serotonergic antidepressants enhance neural plasticity and thereby increase susceptibility to environmental influence; animal work with fluoxetine shows improved outcomes in enriched environments but worse outcomes in stressful ones. The authors note that psychedelics produce rapid neuroplastic changes within hours that may persist for at least a month, implying a similar context sensitivity. Clinical observations and trial data are used to illustrate the point that non-pharmacological factors often predict outcome. The authors reference large depression studies where socioeconomic factors (employment, income, education) were stronger predictors of remission than many clinical features. In STAR*D subanalyses (a cited subsample of 591 patients treated with citalopram), sociodemographic variables predicted response at higher doses, and the magnitude of sociodemographic effects on mood was reportedly 37 times greater at 40 mg than at 20 mg. They also note trajectory analyses showing that about 25% of patients on serotonergic antidepressants followed a non-response trajectory with worse outcomes than placebo, illustrating potential for environment-dependent harms as well as benefits. Turning to clinical-trial practice with psychedelics, the authors describe the common three-part model of psychological support: a preparatory phase (typically 2–8 hours) to build rapport and psychoeducation; a dosing session in which therapists are present but often instructed to refrain from active guidance; and one or two integration sessions to help patients derive insights. Historical psycholytic therapy involved low-to-medium doses (eg, 30–150 µg LSD or 3–15 mg psilocybin) across many sessions (5–25) embedded in longer-term psychodynamic work. By contrast, contemporary high-dose psychedelic therapy uses few administrations (often no more than three), with typical dose ranges in trials given as 250–800 µg LSD or 25–40 mg psilocybin. The authors argue that contemporary "psychological support" as described in industry trial training materials already contains core psychotherapeutic elements: establishment of a therapeutic alliance, fostering self-regulation and capacity to navigate distress, encouragement to engage with internal experience during dosing, and focused integration work. They report that a therapist-training curriculum for a large psilocybin trial explicitly integrates cognitive behavioural therapy, mindfulness-based approaches, acceptance and commitment therapy, and Gestalt focusing, supporting the claim that what is labelled "support" often amounts to process-directed psychotherapy rather than mere safety monitoring. From a regulatory and health-economics angle, the authors point out that HTA bodies assess treatments in the context of real-world care pathways and often assume psychotherapeutic components when judging added therapeutic value and reimbursement eligibility. They cite the example of German HTA evaluation practice in which psychotherapy was considered a prerequisite in comparative assessments. The authors criticise the separation of drug effects from contextual factors by approval agencies and regulators as artificial and at odds with HTA perspectives and clinical reality. Specific to different psychedelics, the authors note that some commentators accept MDMA-assisted psychotherapy as rightly described as psychotherapy-assisted but attribute psilocybin's antidepressant effects purely to the drug. They counter that MDMA and classic psychedelics may share neurobiological mechanisms (a mouse study indicating reopening of a critical period for social reward learning is cited) and that both classes can induce heightened suggestibility, emotional access, and revisions of beliefs or memory recall. Because even minor interpersonal interactions can be experienced as highly meaningful during psychedelic states, the quality of the therapeutic relationship is presented as a key predictor of outcome; conversely, inappropriate accompaniment risks retraumatisation or strengthening maladaptive patterns. Finally, the authors highlight that subjective qualities of the psychedelic experience predict longer-term psychological change, suggesting that therapeutic learning processes mediate much of the benefit. They conclude that ethical and safety considerations imply psychedelic interventions should be delivered within comprehensive psychotherapeutic frameworks by clinicians trained in psychotherapy, and that regulators should formally acknowledge this to ensure minimum standards and prevent cost-saving practices that could compromise outcomes.

Gründer and colleagues interpret the assembled evidence as supporting a single central claim: treating patients with psychedelics is, in effect, psychotherapy and should be conceptualised and regulated as such. They argue that the longstanding mind–brain dualism and reductionist separation of biological and contextual contributors to treatment effects is outdated and counterproductive. By presenting empirical examples, historical practice, and regulatory contrasts, they contend that failing to account for the psychotherapeutic context undermines both safety and efficacy and risks ethical harm to patients. The authors position their view relative to prior research and regulatory debate by noting that HTA processes already tend to evaluate pharmacotherapies in their care-context and that clinical guidelines typically recommend combining pharmacotherapy and psychotherapy for moderate to severe depression. They use that pragmatic stance to argue that approval and reimbursement frameworks should evolve to reflect the integrated nature of psychedelic treatments. The ethical obligations they identify include ensuring therapists are trained to create therapeutic contexts, to support translation of acute experiences into durable change, and to avoid retraumatisation. Limitations and practical challenges are acknowledged indirectly: the authors note resource constraints, market incentives that might favour cost-cutting, and the need for regulatory clarity to prevent compromised standards. Because this article is a Personal View rather than an empirical study, the authors do not present new quantitative analyses; instead they offer a conceptual synthesis and policy-oriented recommendations. They call for research, regulators, and clinicians to abandon reductionist thinking and to develop integrated study designs, implementation strategies, and regulatory requirements that reflect the inseparability of drug and psychosocial context in psychedelic therapy.

The authors conclude that evaluating psychedelic treatments solely in terms of the pharmacological agent both endangers patient safety and neglects accumulating evidence about mechanisms of change that involve psychotherapeutic processes. They urge psychiatry to move beyond reductionist dualism, to integrate knowledge across scientific disciplines, and for regulators to recognise treatment with psychedelics as psychotherapy so that care is delivered ethically and effectively within appropriate therapeutic frameworks.